Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience
This study provides essential insights into the clinical and genomic characteristics of SCUP, advocating for the integration of definitive therapy and immunotherapy in treatment protocols. Further prospective studies are needed to validate these findings and improve patient outcomes.
Authors
- Riham Suleiman (ORCID: https://orcid.org/0000-0002-3335-5022)
- Harry E Fuentes (ORCID: https://orcid.org/0000-0002-7837-8359)
- José C. Villasboas (ORCID: https://orcid.org/0000-0002-2907-0809)
- Joaquín J. García
- Rondell Patrell Graham (ORCID: https://orcid.org/0000-0002-8686-4867)
- Thorvardur R Halfdanarson
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1093/oncolo/oyae333
- Citations
- 4
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 1.68